These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 25897961)
1. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. Rajamuthiah R; Fuchs BB; Conery AL; Kim W; Jayamani E; Kwon B; Ausubel FM; Mylonakis E PLoS One; 2015; 10(4):e0124595. PubMed ID: 25897961 [TBL] [Abstract][Full Text] [Related]
2. The in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens. Levinson MR; Blondeau JM; Rosenkrantz WS; Plowgian CB Vet Dermatol; 2019 Aug; 30(4):314-e87. PubMed ID: 31062461 [TBL] [Abstract][Full Text] [Related]
3. Synergistic combinations of anthelmintic salicylanilides oxyclozanide, rafoxanide, and closantel with colistin eradicates multidrug-resistant colistin-resistant Gram-negative bacilli. Domalaon R; Okunnu O; Zhanel GG; Schweizer F J Antibiot (Tokyo); 2019 Aug; 72(8):605-616. PubMed ID: 31028351 [TBL] [Abstract][Full Text] [Related]
4. The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli. Domalaon R; De Silva PM; Kumar A; Zhanel GG; Schweizer F Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917988 [TBL] [Abstract][Full Text] [Related]
5. The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli. Ayerbe-Algaba R; Gil-Marqués ML; Miró-Canturri A; Parra-Millán R; Pachón-Ibáñez ME; Jiménez-Mejías ME; Pachón J; Smani Y Int J Antimicrob Agents; 2019 Oct; 54(4):507-512. PubMed ID: 31299296 [TBL] [Abstract][Full Text] [Related]
6. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Dowzicky MJ; Park CH Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792 [TBL] [Abstract][Full Text] [Related]
7. Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori. Tharmalingam N; Port J; Castillo D; Mylonakis E Sci Rep; 2018 Feb; 8(1):3701. PubMed ID: 29487357 [TBL] [Abstract][Full Text] [Related]
8. Mechanistic Understanding Enables the Rational Design of Salicylanilide Combination Therapies for Gram-Negative Infections. Copp JN; Pletzer D; Brown AS; Van der Heijden J; Miton CM; Edgar RJ; Rich MH; Little RF; Williams EM; Hancock REW; Tokuriki N; Ackerley DF mBio; 2020 Sep; 11(5):. PubMed ID: 32934086 [TBL] [Abstract][Full Text] [Related]
10. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598 [TBL] [Abstract][Full Text] [Related]
11. Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. Mohammad H; AbdelKhalek A; Abutaleb NS; Seleem MN Int J Antimicrob Agents; 2018 Jun; 51(6):897-904. PubMed ID: 29432868 [TBL] [Abstract][Full Text] [Related]
12. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. Gwisai T; Hollingsworth NR; Cowles S; Tharmalingam N; Mylonakis E; Fuchs BB; Shukla A Biomed Mater; 2017 Jul; 12(4):045010. PubMed ID: 28471351 [TBL] [Abstract][Full Text] [Related]
14. Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile. Rajamuthiah R; Jayamani E; Majed H; Conery AL; Kim W; Kwon B; Fuchs BB; Kelso MJ; Ausubel FM; Mylonakis E Bioorg Med Chem Lett; 2015 Nov; 25(22):5203-7. PubMed ID: 26459212 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia. Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355 [TBL] [Abstract][Full Text] [Related]
16. Repurposing the anthelminthic salicylanilide oxyclozanide against susceptible and clinical resistant Candida albicans strains. Pic E; Burgain A; Sellam A Med Mycol; 2019 Apr; 57(3):387-390. PubMed ID: 29762783 [TBL] [Abstract][Full Text] [Related]
17. Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016. Zhang F; Li Y; Lv Y; Zheng B; Xue F J Glob Antimicrob Resist; 2019 Jun; 17():276-282. PubMed ID: 30611932 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial. Zhang Z; Chen M; Yu Y; Pan S; Liu Y Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activities of Methanol, Ethanol and Supercritical CO2 Extracts of Philippine Piper betle L. on Clinical Isolates of Gram Positive and Gram Negative Bacteria with Transferable Multiple Drug Resistance. Valle DL; Cabrera EC; Puzon JJ; Rivera WL PLoS One; 2016; 11(1):e0146349. PubMed ID: 26741962 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009. Dowzicky MJ Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]